The Food and Drug Administration has issued a cybersecurity advisory for two pieces of hardware that link to cardiac devices like pacemakers and defibrillators, citing a vulnerability that could allow unauthorized access to the programmers.
The FDA said it confirmed that when the two models of programmers, which are made by Minneapolis-based Medtronic, have an internet connection, unauthorized users could exploit the vendor’s network to change the programmers’ functionality.
“While we are not aware of patients who may have been harmed by this particular cyber vulnerability, the risk to patient harm of leaving such a vulnerability unaddressed is too great,” Suzanne Schwartz, a top cybersecurity official at the FDA, said Thursday in a statement.
In response to the security and safety concerns, Medtronic said it disabled the internet-connected software updates for the programmers and that, as of Thursday, a company representative would manually and securely update all of the affected programmers. The FDA approved that Medtronic software update so that medical providers can keep using the programmers without connecting to the internet. The agency said it considers the corrective action a “voluntary recall” undertaken by the manufacturer, as opposed to any mandatory enforcement from the regulator.
Medtronic said it reviewed the vulnerabilities with the FDA and security researchers and concluded that internet-connected software updates for the programmers “may introduce risks that, if not mitigated, could result in harm to patients. To date, we have not observed or received a report of an attack or patient harm.”
Patients’ implanted devices — such as pacemakers — that interact with the programmers do not require an update, Medtronic said. “Physicians should continue to use the programmers for programming, testing and evaluating implanted cardiac devices.”
In August at the Black Hat conference, security researchers demonstrated how a hacker could run malicious firmware on one of the programmers, the CareLink 2090, to make life-threatening changes in care. The security researchers, Billy Rios and Jonathan Butts, said they disclosed the vulnerabilities to Medtronic in January 2017 and criticized the vendor for taking months to address their findings.
Medtronic issued security notices and updates for the programmers in February and June of this year. The February notice, however, claimed that the researchers’ findings “revealed no new potential safety risks based on the existing product security risk assessment.”
In its statement Thursday, Medtronic said that patient safety is its top priority. “Medtronic takes the security of our products seriously, and we continue to proactively minimize and mitigate cybersecurity vulnerabilities during premarket-development and post-market use,” the company added.
Schwartz, who attended the BlackHat presentation, has shown a strong interest in improving vulnerability disclosure in the medical device industry.
“The FDA is committed to protecting patient safety by working with all stakeholders to develop and implement solutions to address cybersecurity issues throughout a product’s total lifecycle,” she said Thursday.